{
  "context": "\n<QuestionSource url=\"https://finance.yahoo.com/quote/PFE\">\n## Summary of Yahoo Finance Article on PFE (Pfizer Inc.)\n\n**Disclaimer:** The article content appears to be a partially extracted Yahoo Finance stock page, with some formatting artifacts and incomplete sections. Some data points may reflect a snapshot from around late February/early March 2026.\n\n---\n\n### Key Price & Trading Data\n- **Previous Close:** $27.10\n- **Open:** $27.16\n- **Day's Range:** $27.09 \u2013 $27.67\n- **52-Week Range:** $20.92 \u2013 $27.94\n- **Volume:** 29,724,256 (vs. Avg. Volume of 47,872,928)\n- **1-Year Price Target (Analyst Consensus):** $28.43\n\n### Valuation & Financials\n- **Market Cap:** $157.21B\n- **Forward P/E:** 9.33 (vs. Trailing P/E of 20.33)\n- **Revenue (TTM):** $62.58B\n- **Net Income (TTM):** $7.75B\n- **Diluted EPS (TTM):** $1.36\n- **Forward Dividend & Yield:** $1.72 (6.22%)\n- **Total Cash:** $14.99B\n\n### Notable News & Analyst Commentary\n- Pfizer announced **Phase 3 trial progress for PADCEV** and received **full FDA approval for BRAFTOVI** in colorectal cancer, representing oncology portfolio advancements.\n- Analysts note **concerns about revenue forecasts and pipeline visibility**.\n- One analyst report flags an **EPS decline expected in 2026**.\n- A Seagen impairment charge and Metsera tolerability data were characterized as **\"incrementally negative\"** for Pfizer.\n- **Earnings Date** is scheduled for **April 28, 2026**.\n- Broader market context noted: major indices were down sharply on the referenced day, with the **VIX jumping ~15% to above 20**, driven by AI disruption fears affecting big tech.\n</QuestionSource>\n"
}